DayFR Euro

Sol-Millennium® launches a revolutionary needle-free injection device for insulin delivery in Canada

Classified in: Health
Topics: Photo/Multimedia, Product/Service

Sol-Millennium® Medical Group, manufacturer of medical devices including syringes for drug delivery and testing, is proud to announce the launch of the InsuJettm needle-free device, designed specifically for insulin delivery in patients diabetics. This innovative technology promises to improve the quality of life of millions of people living with diabetes by eliminating the discomfort associated with traditional needle injections.

The InsuJettm needle-free device uses advanced jet injection technology that delivers precise doses of insulin without the need for needles. This product not only reduces the discomfort usually associated with insulin administration, but also helps relieve anxiety caused by needle injections.

Research shows that many patients fear needles, leading to dosing issues and suboptimal diabetes management. The InsuJettm offers an alternative method of insulin delivery that promotes better adherence to treatment regimens.

“We are excited to introduce InsuJettm to Canada’s diabetes community,” said Chris Sekema, Senior Product Manager at Sol-Millennium® Medical Inc. “Our mission is to create a safer future through innovative solutions. InsuJettm empowers patients by making insulin administration simpler, faster and needle-free. »

InsuJettm has a range of innovative features designed to improve the insulin delivery experience:

  • Needle-free technology – delivers insulin through a high-pressure flow, ensuring a pleasant experience.

  • Accuracy and safety – by making needles unnecessary, InsuJettm significantly reduces the risk of needle-related injuries and needlestick incidents.

  • Portability – ideal for on-the-go lifestyles, allowing patients to manage their diabetes anywhere, anytime.

  • Limits household waste – no sharps containers needed; InsuJettm materials can be disposed of with regular household waste.

InsuJettm has undergone rigorous testing and received approval from Canadian regulatory and health authorities, ensuring its safety and effectiveness for patients [licence HC #109429]. The device is now available for purchase at major pharmacies across Canada.

About Sol-Millennium® Medical Group

Sol-Millennium® Medical Group is one of the world’s largest needle and syringe manufacturers. It is vertically integrated and has locations around the world. Sol-Millennium’s innovative technology delivers successful patient outcomes, saves medications, and improves the clinician and patient experience. With an international sales team dedicated to imparting knowledge and providing exceptional customer service, Sol-Millennium’s goal is to collaborate with healthcare professionals, with a focus on a healthier future.

To learn more about InsuJettm please visit www.solm.com/insujet/ or LinkedIn.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation must always be compared with the source text, which will set a precedent.

These press releases may also interest you

at 05:25

Owkin, the first end-to-end biotechnology using cutting-edge causal AI to drive precision drug discovery, development and diagnosis, and Proscia ® , a global leader in human-assisted pathology solutions…

at 05:25

Sol-Millennium® Medical Group, manufacturer of medical devices including syringes for drug delivery and testing, is proud to announce the launch of the InsuJettm needle-free device, designed specifically for…

at 05:00

On Wednesday, November 20, the spokesperson for the Parti Québécois on Family and Early Childhood Centers (CPE), Joël Arseneau, as well as representatives of the Federation of Health and Social Services (FSSS-CSN) will present has…

at 05:00

A comparative statistical portrait of the situation of women and men in Montreal with regard to various socio-economic, family and health indicators shows that the latter have a lower life expectancy at birth, that they are more…

at 04:01

Nagase Viita Co, Ltd, a member of the NAGASE Group headquartered in Okayama, Japan, is set to expand the range of SOLBIOTE (TM), saccharide-based pharmaceutical excipients, with the launch of high purity SUCROSE SG and low…

19 nov 2024

Product: Dumplings Problem: Food – Allergen – Seafood (shellfish) Distribution: National See affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

Press release sent on November 20, 2024 at 05:25 and distributed by:

-

Related News :